Abstract
This report provides a comprehensive analysis of the global transfusion diagnosis for donor market, projecting steady growth through 2032. It examines the entire industrial chain, from biological raw materials to downstream applications like hospital blood banks and donation centers. Key market drivers include increasing healthcare expenditures, aging populations, and a technological shift toward automated molecular diagnostics and NAT integration. By evaluating product segments, testing methods, and regional dynamics, the study offers strategic insights into high-throughput systems and emerging opportunities in blood management.
Related Questions
US$ 4402 million in 2025; US$ 6479 million in 2032
5.7% (2026-2032)
Grifols, F. Hoffmann-La Roche, Abbott, Bio-Rad Laboratories, Werfen, QuidelOrtho Corporation, AliveDx Holdings Finance, BAG Diagnostics GmbH, Diasorin, Prestige Diagnostics, Atlas Medical GmbH, Lorne Laboratories
Shift toward automated and molecular-based testing, Integration of Nucleic Acid Testing (NAT) with traditional serology, Adoption of Big Data and AI in blood management systems
Summary
Market Overview
Market Size and Forecast
- Market Value (2025): US$ 4402 million
- Projected Market Value (2032): US$ 6479 million
- Compound Annual Growth Rate (CAGR): 5.7% (from 2026 to 2032)
Industry Profitability
- Gross Profit Margin: Major companies in the industry maintain gross profit margins ranging between 50% – 70%.
Definition and Scope
Transfusion Diagnosis for Donors refers to the critical medical screening and testing process performed on blood donors to ensure the safety and compatibility of blood products. This process includes:
- Mandatory Screening for Transfusion-Transmitted Infections (TTIs): Testing for HIV, Hepatitis B and C, and Syphilis using Nucleic Acid Testing (NAT) and ELISA.
- Blood Group Serology: ABO/Rh typing and cross-matching.
These procedures are fundamental to modern hemovigilance, ensuring every blood unit meets stringent clinical safety standards to prevent adverse reactions in recipients.
Industrial Chain Analysis
- Upstream (Providers): Biological raw materials (antigens, antibodies, enzymes), precision optical sensors, microfluidic chips, and high-purity reagents.
- Midstream (Manufacturers): Automated blood screening platforms, molecular diagnostic systems, and immunoassays.
- Downstream (Applications): National and regional blood centers, hospital blood banks, and plasma collection stations.
- Support Services:
- Logistics & Regulation: Cold-chain logistics providers and regulatory bodies.
- Technical Services: Calibration, system maintenance, and integrated blood management software for tracking blood units from collection to clinical transfusion to ensure full traceability and safety.
Market Dynamics
Growth Drivers and Trends
- Automation and Molecular Testing: A significant shift toward automated and molecular-based testing to minimize the "window period" of infection detection.
- Technological Integration: The integration of Nucleic Acid Testing (NAT) with traditional serology to enhance sensitivity.
- Digital Transformation: The adoption of Big Data and AI in blood management systems to optimize inventory and reduce wastage.
- Demographic and Economic Factors: Increasing global healthcare expenditures and aging populations are driving the demand for safe blood supplies.
- Manufacturing Focus: Companies are focusing on high-throughput systems that reduce manual errors while maintaining the highest levels of diagnostic accuracy and safety.
Market Barriers and Opportunities
- Barriers: Stringent regulatory requirements pose a high entry barrier to the market.
- Opportunities: The expansion of blood banking infrastructure in emerging economies provides substantial growth opportunities.
Report Scope and Methodology
This research report, titled “Transfusion Diagnosis for Donor Industry Forecast” by LPI (LP Information), provides a comprehensive analysis of the global landscape.
Key Analytical Focus Areas:
- Historical and Projected Sales: Review of total world sales in 2025 and detailed projections for 2026 through 2032.
- Market Dimensions: Analysis of product segmentation, company formation, revenue, market share, latest developments, and M&A activity.
- Competitive Intelligence: Analysis of leading global companies regarding their portfolios, capabilities, market entry strategies, market positions, and geographic footprints.
- Methodology: A transparent approach based on hundreds of bottom-up qualitative and quantitative market inputs to provide a nuanced view of the market's current state and future trajectory.
Market Segmentation
By Type
- Instruments
- Kits and Reagents
By Diagnostic Purpose
- Blood Grouping & Typing Diagnostics
- Infectious Disease Screening Diagnostics
By Testing Method
- Immunoassay-Based Diagnostics
- Molecular Diagnostics
By Application
- Blood Banks
- Blood Donation/Transfusion Centers
- Others
By Geography
- Americas: United States, Canada, Mexico, Brazil
- APAC: China, Japan, Korea, Southeast Asia, India, Australia
- Europe: Germany, France, UK, Italy, Russia
- Middle East & Africa: Egypt, South Africa, Israel, Turkey, GCC Countries
Competitive Landscape
Key players profiled in this report have been selected based on primary expert input and analysis of their coverage, product portfolio, and market penetration:
- Abbott
- AliveDx Holdings Finance
- Atlas Medical GmbH
- BAG Diagnostics GmbH
- Bio-Rad Laboratories
- Diasorin
- F. Hoffmann-La Roche
- Grifols
- Lorne Laboratories
- Prestige Diagnostics
- QuidelOrtho Corporation
- Werfen
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Transfusion Diagnosis for Donor Market Size (2021-2032)
2.1.2 Transfusion Diagnosis for Donor Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Transfusion Diagnosis for Donor by Country/Region (2021, 2025 & 2032)
2.2 Transfusion Diagnosis for Donor Segment by Type
2.2.1 Instruments
2.2.2 Kits and Reagents
2.2.3 Transfusion Diagnosis for Donor Market Size by Type
- 2.2.3.1 Transfusion Diagnosis for Donor Market Size CAGR by Type (2021 VS 2025 VS 2032)
- 2.2.3.2 Global Transfusion Diagnosis for Donor Market Size Market Share by Type (2021-2026)
2.3 Transfusion Diagnosis for Donor Segment by Diagnostic Purpose
2.3.1 Blood Grouping & Typing Diagnostics
2.3.2 Infectious Disease Screening Diagnostics
2.3.3 Transfusion Diagnosis for Donor Market Size by Diagnostic Purpose
- 2.3.3.1 Transfusion Diagnosis for Donor Market Size CAGR by Diagnostic Purpose (2021 VS 2025 VS 2032)
- 2.3.3.2 Global Transfusion Diagnosis for Donor Market Size Market Share by Diagnostic Purpose (2021-2026)
2.4 Transfusion Diagnosis for Donor Segment by Testing Method
2.4.1 Immunoassay-Based Diagnostics
2.4.2 Molecular Diagnostics
2.4.3 Transfusion Diagnosis for Donor Market Size by Testing Method
- 2.4.3.1 Transfusion Diagnosis for Donor Market Size CAGR by Testing Method (2021 VS 2025 VS 2032)
- 2.4.3.2 Global Transfusion Diagnosis for Donor Market Size Market Share by Testing Method (2021-2026)
2.5 Transfusion Diagnosis for Donor Segment by Application
2.5.1 Blood Banks
2.5.2 Blood Donation/Transfusion Centers
2.5.3 Others
2.5.4 Transfusion Diagnosis for Donor Market Size by Application
- 2.5.4.1 Transfusion Diagnosis for Donor Market Size CAGR by Application (2021 VS 2025 VS 2032)
- 2.5.4.2 Global Transfusion Diagnosis for Donor Market Size Market Share by Application (2021-2026)
3 Transfusion Diagnosis for Donor Market Size by Player
3.1 Transfusion Diagnosis for Donor Market Size Market Share by Player
3.1.1 Global Transfusion Diagnosis for Donor Revenue by Player (2021-2026)
3.1.2 Global Transfusion Diagnosis for Donor Revenue Market Share by Player (2021-2026)
3.2 Global Transfusion Diagnosis for Donor Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Transfusion Diagnosis for Donor by Region
4.1 Transfusion Diagnosis for Donor Market Size by Region (2021-2026)
4.2 Global Transfusion Diagnosis for Donor Annual Revenue by Country/Region (2021-2026)
4.3 Americas Transfusion Diagnosis for Donor Market Size Growth (2021-2026)
4.4 APAC Transfusion Diagnosis for Donor Market Size Growth (2021-2026)
4.5 Europe Transfusion Diagnosis for Donor Market Size Growth (2021-2026)
4.6 Middle East & Africa Transfusion Diagnosis for Donor Market Size Growth (2021-2026)
5 Americas
5.1 Americas Transfusion Diagnosis for Donor Market Size by Country (2021-2026)
5.2 Americas Transfusion Diagnosis for Donor Market Size by Type (2021-2026)
5.3 Americas Transfusion Diagnosis for Donor Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Transfusion Diagnosis for Donor Market Size by Region (2021-2026)
6.2 APAC Transfusion Diagnosis for Donor Market Size by Type (2021-2026)
6.3 APAC Transfusion Diagnosis for Donor Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Transfusion Diagnosis for Donor Market Size by Country (2021-2026)
7.2 Europe Transfusion Diagnosis for Donor Market Size by Type (2021-2026)
7.3 Europe Transfusion Diagnosis for Donor Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Transfusion Diagnosis for Donor by Region (2021-2026)
8.2 Middle East & Africa Transfusion Diagnosis for Donor Market Size by Type (2021-2026)
8.3 Middle East & Africa Transfusion Diagnosis for Donor Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Transfusion Diagnosis for Donor Market Forecast
10.1 Global Transfusion Diagnosis for Donor Forecast by Region (2027-2032)
10.1.1 Global Transfusion Diagnosis for Donor Forecast by Region (2027-2032)
10.1.2 Americas Transfusion Diagnosis for Donor Forecast
10.1.3 APAC Transfusion Diagnosis for Donor Forecast
10.1.4 Europe Transfusion Diagnosis for Donor Forecast
10.1.5 Middle East & Africa Transfusion Diagnosis for Donor Forecast
10.2 Americas Transfusion Diagnosis for Donor Forecast by Country (2027-2032)
10.2.1 United States Market Transfusion Diagnosis for Donor Forecast
10.2.2 Canada Market Transfusion Diagnosis for Donor Forecast
10.2.3 Mexico Market Transfusion Diagnosis for Donor Forecast
10.2.4 Brazil Market Transfusion Diagnosis for Donor Forecast
10.3 APAC Transfusion Diagnosis for Donor Forecast by Region (2027-2032)
10.3.1 China Transfusion Diagnosis for Donor Market Forecast
10.3.2 Japan Market Transfusion Diagnosis for Donor Forecast
10.3.3 Korea Market Transfusion Diagnosis for Donor Forecast
10.3.4 Southeast Asia Market Transfusion Diagnosis for Donor Forecast
10.3.5 India Market Transfusion Diagnosis for Donor Forecast
10.3.6 Australia Market Transfusion Diagnosis for Donor Forecast
10.4 Europe Transfusion Diagnosis for Donor Forecast by Country (2027-2032)
10.4.1 Germany Market Transfusion Diagnosis for Donor Forecast
10.4.2 France Market Transfusion Diagnosis for Donor Forecast
10.4.3 UK Market Transfusion Diagnosis for Donor Forecast
10.4.4 Italy Market Transfusion Diagnosis for Donor Forecast
10.4.5 Russia Market Transfusion Diagnosis for Donor Forecast
10.5 Middle East & Africa Transfusion Diagnosis for Donor Forecast by Region (2027-2032)
10.5.1 Egypt Market Transfusion Diagnosis for Donor Forecast
10.5.2 South Africa Market Transfusion Diagnosis for Donor Forecast
10.5.3 Israel Market Transfusion Diagnosis for Donor Forecast
10.5.4 Turkey Market Transfusion Diagnosis for Donor Forecast
10.6 Global Transfusion Diagnosis for Donor Forecast by Type (2027-2032)
10.7 Global Transfusion Diagnosis for Donor Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Transfusion Diagnosis for Donor Forecast
11 Key Players Analysis
11.1 Grifols
11.1.1 Grifols Company Information
11.1.2 Grifols Transfusion Diagnosis for Donor Product Offered
11.1.3 Grifols Transfusion Diagnosis for Donor Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Grifols Main Business Overview
11.1.5 Grifols Latest Developments
11.2 F. Hoffmann-La Roche
11.2.1 F. Hoffmann-La Roche Company Information
11.2.2 F. Hoffmann-La Roche Transfusion Diagnosis for Donor Product Offered
11.2.3 F. Hoffmann-La Roche Transfusion Diagnosis for Donor Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 F. Hoffmann-La Roche Main Business Overview
11.2.5 F. Hoffmann-La Roche Latest Developments
11.3 Abbott
11.3.1 Abbott Company Information
11.3.2 Abbott Transfusion Diagnosis for Donor Product Offered
11.3.3 Abbott Transfusion Diagnosis for Donor Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Abbott Main Business Overview
11.3.5 Abbott Latest Developments
11.4 Bio-Rad Laboratories
11.4.1 Bio-Rad Laboratories Company Information
11.4.2 Bio-Rad Laboratories Transfusion Diagnosis for Donor Product Offered
11.4.3 Bio-Rad Laboratories Transfusion Diagnosis for Donor Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Bio-Rad Laboratories Main Business Overview
11.4.5 Bio-Rad Laboratories Latest Developments
11.5 Werfen
11.5.1 Werfen Company Information
11.5.2 Werfen Transfusion Diagnosis for Donor Product Offered
11.5.3 Werfen Transfusion Diagnosis for Donor Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Werfen Main Business Overview
11.5.5 Werfen Latest Developments
11.6 QuidelOrtho Corporation
11.6.1 QuidelOrtho Corporation Company Information
11.6.2 QuidelOrtho Corporation Transfusion Diagnosis for Donor Product Offered
11.6.3 QuidelOrtho Corporation Transfusion Diagnosis for Donor Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 QuidelOrtho Corporation Main Business Overview
11.6.5 QuidelOrtho Corporation Latest Developments
11.7 AliveDx Holdings Finance
11.7.1 AliveDx Holdings Finance Company Information
11.7.2 AliveDx Holdings Finance Transfusion Diagnosis for Donor Product Offered
11.7.3 AliveDx Holdings Finance Transfusion Diagnosis for Donor Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 AliveDx Holdings Finance Main Business Overview
11.7.5 AliveDx Holdings Finance Latest Developments
11.8 BAG Diagnostics GmbH
11.8.1 BAG Diagnostics GmbH Company Information
11.8.2 BAG Diagnostics GmbH Transfusion Diagnosis for Donor Product Offered
11.8.3 BAG Diagnostics GmbH Transfusion Diagnosis for Donor Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 BAG Diagnostics GmbH Main Business Overview
11.8.5 BAG Diagnostics GmbH Latest Developments
11.9 Diasorin
11.9.1 Diasorin Company Information
11.9.2 Diasorin Transfusion Diagnosis for Donor Product Offered
11.9.3 Diasorin Transfusion Diagnosis for Donor Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Diasorin Main Business Overview
11.9.5 Diasorin Latest Developments
11.10 Prestige Diagnostics
11.10.1 Prestige Diagnostics Company Information
11.10.2 Prestige Diagnostics Transfusion Diagnosis for Donor Product Offered
11.10.3 Prestige Diagnostics Transfusion Diagnosis for Donor Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Prestige Diagnostics Main Business Overview
11.10.5 Prestige Diagnostics Latest Developments
11.11 Atlas Medical GmbH
11.11.1 Atlas Medical GmbH Company Information
11.11.2 Atlas Medical GmbH Transfusion Diagnosis for Donor Product Offered
11.11.3 Atlas Medical GmbH Transfusion Diagnosis for Donor Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Atlas Medical GmbH Main Business Overview
11.11.5 Atlas Medical GmbH Latest Developments
11.12 Lorne Laboratories
11.12.1 Lorne Laboratories Company Information
11.12.2 Lorne Laboratories Transfusion Diagnosis for Donor Product Offered
11.12.3 Lorne Laboratories Transfusion Diagnosis for Donor Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Lorne Laboratories Main Business Overview
11.12.5 Lorne Laboratories Latest Developments
12 Research Findings and Conclusion